ANIP Ani Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ANIP

Price (delayed)

$75.35

Market cap

$1.73B

P/E Ratio

15.6

Dividend/share

N/A

EPS

$4.83

Enterprise value

$1.98B

?
Relative Growth: Rel. Growth: 93
Relative Strength: Rel. Strength: 24
Relative Valuation: Rel. Valuation: 92
Relative Profitability: Rel. Profitability: 93

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused ...

Highlights
ANIP's P/E is 44% below its last 4 quarters average of 28.0
The company's equity rose by 37% YoY and by 6% QoQ
ANIP's quick ratio is up by 21% year-on-year but it is down by 6% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.anipharmaceuticals.com
Peers: JAZZ TEVA CLDX PFE

Key stats

What are the main financial stats of ANIP

ANIP stock price

How has the Ani Pharmaceuticals stock price performed over time
Intraday
-2.55%
1 week
-1.55%
1 month
-4.8%
1 year
-17.32%
YTD
-4.55%
QTD
-8.98%

Financial performance

How have Ani Pharmaceuticals's revenue and profit performed over time
Revenue
$978.38M
Gross profit
$590.98M
Operating income
$129.35M
Net income
$108.31M
Gross margin
60.4%
Net margin
11.1%
Ani Pharmaceuticals's revenue has increased by 31% YoY and by 6% from the previous quarter
The gross profit has grown by 29% year-on-year and by 5% since the previous quarter
The company's operating income rose by 24% QoQ
Ani Pharmaceuticals's net income has increased by 18% QoQ

Price vs fundamentals

How does ANIP's price correlate with its fundamentals

Growth

What is Ani Pharmaceuticals's growth rate over time

Valuation

What is Ani Pharmaceuticals stock price valuation
ANIP P/E details
P/E
15.6
P/B
2.87
P/S
1.69
EV/EBIT
12.45
EV/EBITDA
8.03
EV/Sales
2.02
ANIP's P/E is 44% below its last 4 quarters average of 28.0
The company's EPS rose by 18% QoQ
The company's equity rose by 37% YoY and by 6% QoQ
The P/B is 16% below the last 4 quarters average of 3.4 but 6% above the 5-year quarterly average of 2.7
Ani Pharmaceuticals's revenue has increased by 31% YoY and by 6% from the previous quarter
The price to sales (P/S) is 20% lower than the 5-year quarterly average of 2.1 and 16% lower than the last 4 quarters average of 2.0

Efficiency

How efficient is Ani Pharmaceuticals business performance
Ani Pharmaceuticals's ROIC has increased by 17% from the previous quarter
The ROA has grown by 15% from the previous quarter
The company's return on sales rose by 12% QoQ
The return on equity has grown by 9% since the previous quarter

Dividends

What is ANIP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIP.

Financial health

How did Ani Pharmaceuticals financials performed over time
Ani Pharmaceuticals's total assets is 67% more than its total liabilities
ANIP's quick ratio is up by 21% year-on-year but it is down by 6% since the previous quarter
The company's current ratio rose by 15% YoY but it fell by 7% QoQ
The debt is 2.2% higher than the equity
The company's equity rose by 37% YoY and by 6% QoQ
The debt to equity has decreased by 28% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.